Medeze Group PCL (MEDEZE.BK) stock: key figures, P/E, revenue and dividend

Health Care · Thailand

Price
5.60 THB
Market cap
5.98 bn THB
P/E (2025)
30.46
P/S (2025)
8.04
Dividend yield
2.86 %
Net margin
26.41 %
Return on equity (ROE)
6.74 %
Return on assets (ROA)
5.65 %

Medeze Group PCL financials

Fiscal year20242025
Revenue829.21 m THB743.65 m THB
Gross profit648.27 m THB547.32 m THB
Operating income363.74 m THB228.31 m THB
EBIT387.08 m THB250.88 m THB
Net income338.74 m THB196.38 m THB
Diluted EPS – continuing operations0.32 THB0.18 THB

Full history since 2023, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Medeze Group PCL

Medeze Group Public Company Limited engages in collection and storage of stem cells for use in medication in Thailand, Vietnam, Cambodia, Philippines, and internationally. The company operates through four segments: Stem Cells; Natural Killer Cells; Others; and Sales of Products. It also provides sorting, cultivation, and development of stem cells; testing services to test the performance and count the number of natural killer cells. In addition, the company is involved in research, develops, and collects data on all types of human cellular activities and medical laboratory tests. Further, the company sells dietary supplements, cosmetics, and dermo cosmetics. Medeze Group Public Company Limited was founded in 2010 and is based in Nakhon Pathom, Thailand.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.